# Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f70a7f47
Ticker: XLO
Company: Xilio Therapeutics
Source: Xilio Therapeutics
Published: 2026-07-06 20:30 EST
## Summary

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...

## Article Body
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $9.22 per share, which is equal to the closing price of the company’s common stock on July 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn ( Xilio Therapeutics, Inc. ).

Investor Contact Alex Lobo, Precision AQ Alex.lobo@precisionaq.com

Media Contact Josie Butler, 1AB josie@1abmedia.com
## Recent Company News
- 2026-07-06 20:30 EST — [Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f70a7f47) — Source: Xilio Therapeutics
- 2026-06-29 11:30 EST — [Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer](https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-d248a423) — Source: Xilio Therapeutics
- 2026-05-12 11:30 EST — [Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates](https://biopharmsignal.com/news/XLO/xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pip-859a3b0c) — Source: Xilio Therapeutics
- 2026-05-07 20:30 EST — [Xilio Therapeutics Announces Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--057e4f7c) — Source: Xilio Therapeutics
- 2026-04-17 20:01 EST — [Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx-61e9b86b) — Source: Xilio Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)